CSBio CSBio

X
[{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings Launches Muna Therapeutics with US$ 73M Series A","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Muna Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Muna was founded in 2020 by progranulin pathway thought leader Professor Simon Glerup and his team from Aarhus University, Denmark, in collaboration with Novo Seeds, the early-stage investment team of Novo Holdings.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novo Holdings

            Deal Size: $73.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY